Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOLERA: Sequential Rituximab and Abatacept in RA
NCT04120831Phase 2Unknown
- Sponsor
- FAU Erlangen-Nürnberg Medical Faculty
- Start
- Oct 2019
- Primary completion
- Sep 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of abatacept in rheumatoid arthritis (RA) (2 arms), sponsored by FAU Erlangen-Nürnberg Medical Faculty. Primary endpoint: Rate of anti-CCP2 antibody seroconversion at 52 weeks. Status: unknown.
02
Drugs
abatacept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04120831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04120831.